These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 25756831

  • 1. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
    D'Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF, AUGMENT COPD study investigators.
    Respir Res; 2014 Oct 14; 15(1):123. PubMed ID: 25756831
    [Abstract] [Full Text] [Related]

  • 2. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis.
    Miravitlles M, Chapman KR, Chuecos F, Ribera A, Gil EG.
    Int J Chron Obstruct Pulmon Dis; 2016 Oct 14; 11():2041-53. PubMed ID: 27621610
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.
    D'Urzo AD, Singh D, Donohue JF, Kerwin EM, Ribera A, Molins E, Chuecos F, Jarreta D, Gil EG.
    Int J Chron Obstruct Pulmon Dis; 2019 Oct 14; 14():479-491. PubMed ID: 30880938
    [Abstract] [Full Text] [Related]

  • 4. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
    Ni H, Moe S, Soe Z, Myint KT, Viswanathan KN.
    Cochrane Database Syst Rev; 2018 Dec 11; 12(12):CD011594. PubMed ID: 30536566
    [Abstract] [Full Text] [Related]

  • 5. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
    Singh D, D'Urzo AD, Chuecos F, Muñoz A, Garcia Gil E.
    Respir Res; 2017 May 30; 18(1):106. PubMed ID: 28558833
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study.
    Singh D, Jones PW, Bateman ED, Korn S, Serra C, Molins E, Caracta C, Gil EG, Leselbaum A.
    BMC Pulm Med; 2014 Nov 18; 14():178. PubMed ID: 25404569
    [Abstract] [Full Text] [Related]

  • 7. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).
    Bateman ED, Chapman KR, Singh D, D'Urzo AD, Molins E, Leselbaum A, Gil EG.
    Respir Res; 2015 Aug 02; 16(1):92. PubMed ID: 26233481
    [Abstract] [Full Text] [Related]

  • 8. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.
    Donohue JF, Soong W, Wu X, Shrestha P, Lei A.
    Respir Med; 2016 Jul 02; 116():41-8. PubMed ID: 27296819
    [Abstract] [Full Text] [Related]

  • 9. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.
    Sethi S, Kerwin E, Watz H, Ferguson GT, Mroz RM, Segarra R, Molins E, Jarreta D, Garcia Gil E.
    Int J Chron Obstruct Pulmon Dis; 2019 Jul 02; 14():667-682. PubMed ID: 30962681
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.
    Jones PW, Rennard SI, Agusti A, Chanez P, Magnussen H, Fabbri L, Donohue JF, Bateman ED, Gross NJ, Lamarca R, Caracta C, Gil EG.
    Respir Res; 2011 Apr 26; 12(1):55. PubMed ID: 21518460
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of aclidinium/formoterol versus monotherapies and aclidinium versus placebo in Chinese and other Asian patients with moderate-to-severe COPD: The AVANT Phase 3 study.
    Sun Y, Molins E, Daoud SZ, Trivedi R, Stewart C, Lamarca R, Bharali P, Garcia-Gil E.
    Respir Med; 2023 Nov 26; 218():107393. PubMed ID: 37640273
    [Abstract] [Full Text] [Related]

  • 12. Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combinations in COPD.
    Siddiqui MK, Shukla P, Jenkins M, Ouwens M, Guranlioglu D, Darken P, Biswas M.
    Ther Adv Respir Dis; 2019 Nov 26; 13():1753466619894502. PubMed ID: 31868101
    [Abstract] [Full Text] [Related]

  • 13. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
    Martinez FJ, Rabe KF, Lipworth BJ, Arora S, Jenkins M, Martin UJ, Reisner C.
    Int J Chron Obstruct Pulmon Dis; 2020 Nov 26; 15():99-106. PubMed ID: 32021148
    [Abstract] [Full Text] [Related]

  • 14. A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease.
    D'Urzo A, Rennard S, Kerwin E, Donohue JF, Lei A, Molins E, Leselbaum A.
    Respir Med; 2017 Apr 26; 125():39-48. PubMed ID: 28340861
    [Abstract] [Full Text] [Related]

  • 15. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
    Chen R, Zhong N, Wang HY, Zhao L, Mei X, Qin Z, Huang J, Assam PN, Maes A, Siddiqui S, Martin UJ, Reisner C.
    Int J Chron Obstruct Pulmon Dis; 2020 Apr 26; 15():43-56. PubMed ID: 32021143
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison.
    Medic G, Lindner L, van der Weijden M, Karabis A.
    Adv Ther; 2016 Mar 26; 33(3):379-99. PubMed ID: 26883661
    [Abstract] [Full Text] [Related]

  • 17. Aclidinium bromide and formoterol fumarate for the maintenance treatment of chronic obstructive pulmonary disease.
    Haley R, Gupta N, Sethi S.
    Expert Rev Clin Pharmacol; 2020 Feb 26; 13(2):103-113. PubMed ID: 31951778
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
    Zheng J, Baldi S, Zhao L, Li H, Lee KH, Singh D, Papi A, Grapin F, Guasconi A, Georges G.
    Respir Res; 2021 Mar 23; 22(1):90. PubMed ID: 33757520
    [Abstract] [Full Text] [Related]

  • 19. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients.
    Rennard SI, Scanlon PD, Ferguson GT, Rekeda L, Maurer BT, Garcia Gil E, Caracta CF.
    Clin Drug Investig; 2013 Dec 23; 33(12):893-904. PubMed ID: 24085591
    [Abstract] [Full Text] [Related]

  • 20. Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.
    Babu KS, Morjaria JB.
    Ther Adv Respir Dis; 2015 Apr 23; 9(2):56-68. PubMed ID: 25754881
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.